Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/05/2790782/0/en/Replimune-Shares-Initial-Primary-Analysis-Results-from-CERPASS-Clinical-Trial-in-Advanced-Cutaneous-Squamous-Cell-Carcinoma-and-Presents-New-Data-from-IGNYTE-Clinical-Trial-of-RP1-.html

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not meet either of the two primary endpoints

Read more at globenewswire.com

Related news for (REPL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.